Supplementing Patient-Reported Outcomes: How Accurate Are Patient-Reported Data Online?

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

The pharmaceutical industry’s interest in patient-reported outcomes (PROs) has steady grown since the FDA and EMA released their respective guidances on the subject.  Now, pharma and device companies seek out the best ways to infuse their product support with the patient voice.  For many companies, this can mean looking not only to clinical trials which use PRO measures, but also to available pharmaceutical Big Data. As the patient population becomes more tech savvy, more and more patient data is available online. Continue reading


Medical Device HEOR Groups Use PROs to Support Reimbursement Conversations

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Health economics groups are facing more competitive reimbursement processes worldwide.  To navigate these increasingly difficult negotiations, many medical device HEOR groups are looking to patient-reported outcomes (PROs) to improve their value propositions. One interviewed HEOR consultant explained, “Before PROs, you had a lot of clinician-completed measures and clinician rating scales. Now the FDA and stakeholders want to see how treatments are actually impacting patients, and PROs give the patients a voice in the trial.” Continue reading


The Superstars of Digital Healthcare: MM&M Lists ‘Top 40 Healthcare Transformers’

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Innovations abound within the pharmaceutical digital marketing space. As a whole, the industry has worked to increase the availability of healthcare information and better address the needs of healthcare consumers. In its recent “Top 40 Healthcare Transformers” article, Medical Marketing and Media provides a snapshot of some of the leading industry innovators.  Many executives have leveraged online platforms to connect with unique industry stakeholders.  Others have modified the way patients receive healthcare by creating new—or rethinking existing— telemedicine platforms.  In some cases, companies have even begun connecting patients with doctors who are prepared to make house calls.  Continue reading


Pilot New Medical Science Liaison Programs with Contract MSLs

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Life sciences companies point to the outsourcing of MSLs as a way for field-based medical teams to pilot new programs and activities while avoiding the risks of taking on fulltime headcount.  Whether the activity is HEOR, managed care, or whether it is testing a hybrid medical science liaison position, it is fairly simple to contract one or two experienced MSLs to pilot it out in the field, see how it goes, and then learn the results. Continue reading


Big Data Storage and Privacy in the Pharmaceutical Industry

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Within the last few years, Big Data has become one of the most recognizable buzzwords in marketing.  Especially as the healthcare industry moves more towards cultivating a strong digital presence, life sciences industries are looking for ways to use these data.  With access to a plethora of information — from electronic medical records (EMRs) to clinical trial results — firms are seeking out new ways to leverage pharmaceutical Big Data. Continue reading


Risk-Based Monitoring (RBM) Defrays High Monitoring Costs during Longer Clinical Trials

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

For most life sciences companies, on-site monitoring is a significant expense during clinical studies.  In fact, one CRO executive interviewed by CEI’s analysts suggests that monitoring budgets — which supports the number of monitors required for the trial and their travel expenses — can equal up to 60% of overall clinical trial costs.  To defray some of these costs, many pharmaceutical companies are turning to risk-based monitoring (RBM) as an effective cost-reduction technique. Continue reading


Health Outcomes, Patient-Reported Outcomes and Real-World Data Most Preferred Forms of Big Data

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Because of the varied nature of pharmaceutical Big Data, companies have access to information capable of supporting a number of goals throughout products’ lifecycles.  Teams companywide are able to implement prospective studies to support clinical trials, impact reimbursement conversations with payers and demonstrate product effectiveness.  Data usage for these prospective studies varies depending on the teams’ goals and available information. Continue reading



Medical Information Leaders Justifying Resource Increases with Increased Responsibilities

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Just like virtually every other function within pharmaceutical organizations, medical information teams must make strong cases to increase — and often simply justify — budget and personnel resources.  For many medical information leaders, one avenue to justifying their resources is an expansion of their teams’ duties beyond the primary duty of answering inquiries placed by internal and external clients. Continue reading


HEOR Data Needs to be Tailored to Match Market Needs

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When health economics groups are working on developing HEOR data, they need to keep in mind the different gaps that the research may be needed to fill.  Depending on the market, whether right at launch or years afterwards, payers may see product’s position significantly strengthened by the appropriate HEOR data.  Developing the right information can require customization based on geography or based on the competitive landscape. Continue reading